Brief: Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
24/09/2024 13:32
Sept 24 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX ANNOUNCES POSITIVE DSMB RECOMMENDATION TO INITIATE
THE
PHASE II STAGE OF ITS PHASE I/II TRIAL OF ALLOCETRA IN PATIENTS
WITH MODERATE TO SEVERE KNEE OSTEOARTHRITIS
* ENLIVEX THERAPEUTICS LTD - NO SERIOUS ADVERSE REACTIONS
REPORTED
IN PHASE I SAFETY RUN-IN
* ENLIVEX THERAPEUTICS LTD - DSMB CONFIRMS SAFETY PROFILE
ALLOWS
PROGRESSION TO PHASE II
Source text for Eikon: ID:nGNX126TYP
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment